Pfizer (NYSE:PFE) Receives “Buy” Rating from Guggenheim

Pfizer (NYSE:PFE)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research report issued to clients and investors on Tuesday,Benzinga reports.

A number of other equities analysts have also recently weighed in on the stock. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

PFE opened at $26.18 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a fifty day moving average price of $26.19 and a 200 day moving average price of $27.08. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54. The stock has a market cap of $148.35 billion, a P/E ratio of 18.57, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the business posted $0.10 EPS. The business’s revenue was up 24.7% compared to the same quarter last year. Equities research analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. DSG Capital Advisors LLC acquired a new position in Pfizer in the fourth quarter valued at about $281,000. Chancellor Financial Group WB LP acquired a new position in Pfizer in the fourth quarter valued at about $290,000. 111 Capital acquired a new position in Pfizer in the fourth quarter valued at about $509,000. Thoma Capital Management LLC acquired a new position in Pfizer in the fourth quarter valued at about $523,000. Finally, PKO Investment Management Joint Stock Co acquired a new position in Pfizer in the fourth quarter valued at about $2,096,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.